ArticlePediatric nephrology (Berlin, Germany)2026
Differential clinical characteristics of Chinese children with primary hyperoxaluria type 3.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to the letter of Deng et al.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a rare autosomal recessive disorder, primary hyperoxaluria type 3 (PH3) presents diagnostic challenges. Our comparative analysis of clinical characteristics between patients with PH3 and non-PH patients revealed distinct characteristics that may facilitate the diagnosis of PH3.
methodsClinical data from pediatric patients with urolithiasis who had undergone whole-exome sequencing from 2016-2024 were analyzed. Patients were divided into PH3 group and non-PH group on the basis of genetic testing.
resultsCompared with non-PH patients, PH3 patients presented earlier onset (0.9 vs. 2.0 years, P = 0.021), higher incidence of nephrocalcinosis (22.22% vs. 3.17%, P = 0.008), higher serum calcium (2.55 vs. 2.49 mmol/L, P = 0.007), higher urinary oxalate levels (333.70 vs. 170.84 µg/mg, P = 0.008), higher urinary citrate levels (195.22 vs. 123.13 µg/mg, P = 0.015), lower urinary uric acid levels (838.44 vs. 1177.42 µg/mg, P = 0.040), and lower urinary calcium levels (113.27 vs. 352.21 µg/mg, P < 0.001). Subgroup analyses revealed that patients with PH3 had higher urinary oxalate levels (333.70 vs. 170.84 µg/mg, P = 0.042) than patients with cystinuria. Compared with patients in the other stone-related gene mutation groups, patients in the PH3 group presented earlier onset (0.9 vs. 2.5 years, P = 0.029), higher urinary oxalate levels (333.70 vs. 105.30 µg/mg, P = 0.045), higher urinary citrate levels (195.22 vs. 59.36 µg/mg, P < 0.001), and lower urinary calcium levels (113.27 vs. 421.24 µg/mg, P = 0.003). Patients with PH3 had greater incidence of nephrocalcinosis (22.22% vs. 0, P = 0.007), higher serum calcium levels (2.55 vs. 2.49 mmol/L, P = 0.030), higher urinary oxalate levels (333.70 vs. 182.74 µg/mg, P = 0.048) and lower urinary calcium levels (113.27 vs. 368.14 µg/mg, P = 0.004) than patients with negative molecular diagnoses.
conclusionPediatric patients with PH3 are characterized by early onset, nephrocalcinosis, increased urinary oxalate excretion and lower urinary calcium excretion, which could provide guidance for earlier diagnosis of patients with PH3.
Indexed as
Identifiers
41238966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.